Taiho Oncology and Taiho Pharmaceutical gain FDA approval for Lonsurf
2023-08-03
上市批准临床结果临床3期
Preview
来源: Pharmaceutical Technology
Lonsurf has been approved to treat adult patients with metastatic colorectal cancer. Credit: crystal light / Shutterstock.com.
Taiho Oncology and Taiho Pharmaceutical have received approval from the US Food and Drug Administration (FDA) for Lonsurf to treat adult patients with metastatic colorectal cancer (mCRC).
The approval is intended for using Lonsurf either as a single agent or with bevacizumab in patients previously treated with oxaliplatin, fluoropyrimidine and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type [without mutations], with an anti-EGFR therapy.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Anamorelin Hydrochloride in Chemotherapy Effects GlobalData
Preview
来源: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Pancreatic extract-based compositions GlobalData
View allCompanies IntelligenceTaiho Pharmaceutical Co LtdTaiho Oncology IncSUN LIGHT CORPORATIONView all
Taiho Pharmaceutical discovered and developed Lonsurf, an oral nucleoside antitumour agent.
It contains trifluridine, a nucleoside analogue based on thymidine, along with tipiracil, an inhibitor of thymidine phosphorylase (TP). This combination enhances exposure to trifluridine by inhibiting its metabolism by TP.
Based on data from the Phase III SUNLIGHT study, the FDA granted approval for the combination of Lonsurf and bevacizumab.
This combination showed improvements in progression-free survival and overall survival in patients with mCRC after disease progression or who could not tolerate two previous chemotherapy regimens.
These results were compared to the outcomes using LONSURF alone.
Taiho Oncology president and CEO Timothy Whitten stated: “The treatment of advanced colorectal cancer has been a core focus of our work at Taiho Oncology since our inception and with good reason: approximately 22% of patients with colorectal cancer in the US are diagnosed after the cancer has metastasised.
“The FDA approval of Lonsurf in combination with bevacizumab is another example of how we are continuing to advance care in this disease and provide new hope to patients and their families.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。